...
首页> 外文期刊>Tropical Medicine and International Health: TM and IH >Predictors for mortality and loss to follow-up among children receiving anti-retroviral therapy in Lilongwe, Malawi.
【24h】

Predictors for mortality and loss to follow-up among children receiving anti-retroviral therapy in Lilongwe, Malawi.

机译:马拉维利隆圭接受抗逆转录病毒治疗的儿童的死亡率和随访损失的预测指标。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVES: To determine predictors of mortality in children on anti-retroviral therapy (ART) who attended the Paediatric HIV Clinic at Kamuzu Central Hospital in Lilongwe, Malawi. METHODS: Retrospective case cohort study by chart review of children who had started ART between October 2004 and May 2006. Bivariable and multivariable analysis were performed with and without defaulters to evaluate associations according to vital status and to identify independent predictors of mortality. RESULTS: Forty-one of 258 children (15.9%) were deceased, 185 (71.7%) were alive, and 32 (12.4%) had defaulted: 51% were female, 7% were under 18 months, 26% were 18 months to 5 years, and 54% were >5 years of age. Most were WHO stage III or IV (56% and 37%, respectively). On multivariate analysis, factors most strongly associated with mortality and defaulting were age <18 months [hazards ratio (HR) 2.11 (95% CI 1.0-4.51)] and WHO stage IV [HR 2.00 (95% CI 1.07-3.76)]. CONCLUSIONS: To improve outcomes of HIV-positive children, they must be identified and treated early, specifically children under 18 months of age. Access to infant diagnostic procedures must be improved to allow effective initiation of ART in infants at higher risk of death.
机译:目的:确定接受抗逆转录病毒治疗(ART)的儿童死亡率的预测因素,这些儿童曾在马拉维利隆圭的Kamuzu中心医院的儿科HIV诊所就诊。方法:对2004年10月至2006年5月开始接受抗逆转录病毒治疗的儿童进行图表回顾性回顾性病例队列研究。进行双变量和多变量分析(有或没有默认者),以根据生命状况评估关联并确定独立的死亡率预测因子。结果:258名儿童中有41名(15.9%)死了,有185名(71.7%)活着,有32名(12.4%)有违约:51%为女性,7%为18个月以下,26%为18个月以下5岁,其中54%的年龄大于5岁。大多数为世卫组织第三或第四阶段(分别为56%和37%)。在多变量分析中,与死亡率和违约率最密切相关的因素是年龄<18个月[危险比(HR)2.11(95%CI 1.0-4.51)]和WHO的IV期[HR 2.00(95%CI 1.07-3.76)]。结论:为改善艾滋病毒阳性儿童的结局,必须及早发现并治疗儿童,特别是18个月以下的儿童。必须改善获得婴儿诊断程序的途径,以使死亡风险较高的婴儿能够有效地开始抗病毒治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号